RVT-1401 (Administered via subcutaneous injection)
Phase 2Terminated 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Graves' Ophthalmopathy (GO)
Conditions
Graves' Ophthalmopathy (GO)
Trial Timeline
Jul 23, 2019 → Apr 15, 2021
NCT ID
NCT03938545About RVT-1401 (Administered via subcutaneous injection)
RVT-1401 (Administered via subcutaneous injection) is a phase 2 stage product being developed by Immunovant for Graves' Ophthalmopathy (GO). The current trial status is terminated. This product is registered under clinical trial identifier NCT03938545. Target conditions include Graves' Ophthalmopathy (GO).
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03938545 | Phase 2 | Terminated |
Competing Products
6 competing products in Graves' Ophthalmopathy (GO)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CFZ533 | Novartis | Phase 2 | 52 |
| Rilzabrutinib dose 1 + Rilzabrutinib dose 2 | Sanofi | Phase 2 | 51 |
| RVT-1401 | Immunovant | Phase 2 | 49 |
| IMVT-1402 | Immunovant | Phase 2 | 49 |
| IMVT-1402 + IMVT-1402 + Placebo | Immunovant | Phase 2 | 49 |
| IMVT-1402 + IMVT-1402 + Placebo | Immunovant | Phase 2 | 49 |